Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
OHR Pharmaceutical. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
OHR Pharmaceutical's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OHR Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare OHR Pharmaceutical's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare OHR Pharmaceutical's earnings growth to the Germany market average as no estimate data is available.
Unable to compare OHR Pharmaceutical's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if OHR Pharmaceutical is high growth as no earnings estimate data is available.
Unable to determine if OHR Pharmaceutical is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
OHR Pharmaceutical's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
OHR Pharmaceutical's finances.
The net worth of a company is the difference between its assets and liabilities.
OHR Pharmaceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
OHR Pharmaceutical has no long term commitments.
This treemap shows a more detailed breakdown of
OHR Pharmaceutical's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
OHR Pharmaceutical has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Jason Scott Slakter, M.D., has been the Chief Executive Officer and President of Ohr Pharmaceutical, Inc. since September 2015. Dr. Slakter is a Partner at Vitreous-Retina-Macula Consultants of New York. He is the Founder of the Digital Angiography Reading Center (DARC) in New York and also its Chairman and Medical Monitor. He serves as an Editor-in-Chief of Retinal Physician. Dr. Slakter served as the Chief Medical Officer of Ohr Pharmaceutical, Inc. from May 2014 to August 7, 2015. He co-founded SKS Ocular, LLC in 2010 and served as its Chief Executive Officer. Dr. Slakter served as the Clinical Advisor of Acucela Inc. He served as Chief Medical Officer of Potentia Pharmaceuticals, Inc. Dr. Slakter practices at the Vitreous-Retina-Macula Consultants in New York. He continued to oversee the ongoing clinical activities at Alcon related to the lead product related to complement inhibition for treatment of age-related macular degeneration. He served as an Advisor of Kubota Pharmaceutical Holdings Co., Ltd. He served as a Principal Investigator in the Clinical Trials for photodynamic therapy for the treatment of wet AMD and is conducting clinical studies for the treatment of central serous chorioretinopathy. Dr. Slakter is an attending surgeon and Surgeon Director of the Manhattan Eye, Ear and Throat Hospital. His expertise in macular disease diagnostics is extensive. He played a leading role and is widely published in the development of digital indocyanine green angiography (ICG) for the evaluation and management of macular degeneration and chorioretinal inflammatory disease. He is the Founder of the Digital Angiography Reading Center and serves as its Director. He has been a Director of Ohr Pharmaceutical, Inc. since January 8, 2015. Dr. Slakter serves as a Member of Clinical Advisory Board at iCo Therapeutics Inc. He has been a Member of AMD Scientific Advisory Board at Apellis Pharmaceuticals, Inc. since July 2015. He serves as a Member of Advisory Board at Paloma Pharmaceuticals Inc. He serves as a Member of the Medical Advisory Board of Quark Pharmaceuticals Inc. (formerly known as Quark Biotech Inc.). Dr. Slakter serves as a Member of Scientific Advisory Board of Tyrogenex, Inc. He serves as a Member of the Scientific Advisory Board of Sirion Holdings Inc. (formerly Sirion Therapeutics Inc.). He served as a Member of Strategic Advisory Board of iCo Therapeutics Inc. since June 2006. He served as a Member of Scientific Advisory Board of Acuity Pharmaceuticals Inc. since June 2005. He served as a Member of Scientific Advisory Board of Ohr Pharmaceutical, Inc. since May 1, 2012 and Potentia Pharmaceuticals Inc. He served as a Member of Clinical Advisory Board for Othera Pharmaceuticals, Inc. He is on the editorial board of Retina and serves as a scientific reviewer for major scientific ophthalmic journals. He is a world-renowned retinal specialist who has been involved in the design and application of numerous diagnostic and therapeutic techniques. Dr. Slakter is a Clinical Professor of ophthalmology of New York University School of Medicine, is internationally recognized for his work in the development of novel diagnostic and therapeutic approaches for retinal conditions. Dr. Slakter is an internationally recognized retinal specialist who has published more than 100 papers. He also is an Author of the first comprehensive text on the subject of ICG angiography. Dr. Slakter is a member of numerous medical organizations including The American Ophthalmological Society, The Macula Society, Ophthalmological Society The Retina Society and The American Society of Retina Spnecialists. Dr. Slakter received the American Academy of Ophthalmology Senior Honor Award, the Macula Society's Richard, Hinda Rosenthal Award and the Helen Keller Manhattan League Award. He is a board certified vitreoretinal surgeon and macular disease specialist at the Manhattan Eye, Ear and Throat Hospital. Dr. Slakter holds an M.D. from Albert Einstein College of Medicine, Bronx and completed his residency at Manhattan Eye, Ear & Throat Hospital.
Jason's compensation has increased whilst company is loss making.
Jason's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the OHR Pharmaceutical management team is about average.
CEO, President & Director
CFO, VP of Business Development & Secretary
Chief Scientific Officer
Head of Preclinical & Regulatory Affairs
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the OHR Pharmaceutical board of directors is about average.
OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase’s peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.